Shield Therapeutics (1JS) Financial Statements

2 Followers

Shield Therapeutics Financial Overview

Shield Therapeutics's market cap is currently €80.34M. The company's EPS TTM is €-0.0174; its P/E ratio is -4.93; Shield Therapeutics is scheduled to report earnings on April 9, 2026, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Dec 24	Dec 23	Dec 22	Jun 22
Income Statement
Total Revenue	$ 50.74M	$ 32.18M	$ 16.54M	$ 4.48M	$ 1.52M
Gross Profit	$ 22.38M	$ 13.22M	$ 5.09M	$ 2.00M	$ -1.67M
Operating Income	$ -10.30M	$ -22.87M	$ -31.33M	$ -26.39M	$ -20.41M
EBITDA	$ -9.16M	$ -20.74M	$ -38.28M	$ -46.07M	$ -17.69M
Net Income	$ -18.03M	$ -26.61M	$ -33.29M	$ -40.44M	$ -19.34M
Balance Sheet
Cash & Short-Term Investments	$ 11.63M	$ 7.02M	$ 17.63M	$ 2.82M	$ 12.12M
Total Assets	$ 65.24M	$ 57.42M	$ 48.80M	$ 22.07M	$ 44.41M
Total Debt	$ 30.15M	$ 26.34M	$ 25.80M	$ 6.10M	$ 156.00K
Net Debt	$ 18.52M	$ 19.33M	$ 8.17M	$ 3.28M	$ -11.96M
Total Liabilities	$ 80.32M	$ 58.74M	$ 33.77M	$ 16.65M	$ 3.38M
Stockholders' Equity	$ -15.08M	$ -1.32M	$ 11.79M	$ 5.43M	$ 40.69M
Cash Flow
Free Cash Flow	$ -8.83M	$ -8.80M	$ -50.65M	$ -20.14M	$ -18.80M
Operating Cash Flow	$ -8.81M	$ -8.77M	$ -46.93M	$ -18.25M	$ -16.74M
Investing Cash Flow	$ -306.29K	$ -2.37M	$ -3.07M	$ -1.70M	$ -2.05M
Financing Cash Flow	$ 13.75M	$ 5.26M	$ 62.77M	$ 7.71M	$ 27.58M

Currency in USD

Shield Therapeutics Earnings and Revenue History

Income Statement >

Shield Therapeutics Debt to Assets

Balance Sheet >

Shield Therapeutics Cash Flow

Cash Flow >

Shield Therapeutics Forecast EPS vs Actual EPS

Earnings >